2seventy bio Reports First Quarter Financial Results and Recent Operational Progress
2seventy bio, Inc. (TSVT)
Company Research
Source: Business Wire
U.S. FDA Approval of Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy; Commercial Launch UnderwayCompletion of R&D Pipeline Divestiture to Regeneron Sets Company on Track to Focus Exclusively on Development and Commercialization of Abecma with Streamlined Cost StructureAbecma generated $52 million U.S. commercial revenue in the first quarter of 2024Ended quarter with $181.4 million cash, cash equivalents, and marketable securities; cash runway beyond 2027Conference call today at 8:00 AM ET CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), today reported financial results and recent highlights for the first quarter ended March 31, 2024.“In the first quarter of 2024, we have successfully completed a strategic re-alignment to focus exclusively on Abecma, seeking to impact many more patients in earlier lines and return to commercial growth. In turn, we are focused on reaching financial sustainability and creati
Show less
Read more
Impact Snapshot
Event Time:
TSVT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TSVT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TSVT alerts
High impacting 2seventy bio, Inc. news events
Weekly update
A roundup of the hottest topics
TSVT
News
- 2seventy bio, Inc. (NASDAQ: TSVT) was upgraded by analysts at Canaccord Genuity Group Inc. to a "strong-buy" rating.MarketBeat
- 2seventy bio, Inc. (NASDAQ: TSVT) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $12.00 to $11.00. They now have a "buy" rating on the stock.MarketBeat
- 2seventy bio Reports First Quarter Financial Results and Recent Operational Progress [Yahoo! Finance]Yahoo! Finance
- 2seventy bio to Report First Quarter 2024 Financial Results on May 8, 2024 [Yahoo! Finance]Yahoo! Finance
- 2seventy bio to Report First Quarter 2024 Financial Results on May 8, 2024Business Wire
TSVT
Earnings
- 5/8/24 - Miss
TSVT
Sec Filings
- 5/16/24 - Form 4
- 5/9/24 - Form 10-Q
- 5/8/24 - Form 8-K
- TSVT's page on the SEC website